Day: April 7, 2021

LEI Code 213800SYIQPA3L3T1Q68 Joint Announcement Albion Development VCT PLC, Albion Enterprise VCT PLC, Albion Technology & General VCT PLC, Crown Place VCT PLC and Kings Arms Yard VCT PLC (together “the Companies”) Issue of a Supplementary Prospectus The Boards of the Companies announce that they have published a supplementary prospectus (the “Supplementary Prospectus”) relating to the offers for subscription for new Ordinary Shares in each of the Companies to raise, in aggregate, up to £45 million (before issue costs) (the “Offers”). The Supplementary Prospectus is a regulatory requirement under the Prospectus Regulation Rules and Section 87G of Financial Services and Market Act 2000 following the publication of the annual report and accounts for the year ended 31 December 2020 by each of Albion Development...

LEI Code 213800OVSRDHRJBMO720 Joint Announcement Albion Development VCT PLC, Albion Enterprise VCT PLC, Albion Technology & General VCT PLC, Crown Place VCT PLC and Kings Arms Yard VCT PLC (together “the Companies”) Issue of a Supplementary Prospectus The Boards of the Companies announce that they have published a supplementary prospectus (the “Supplementary Prospectus”) relating to the offers for subscription for new Ordinary Shares in each of the Companies to raise, in aggregate, up to £45 million (before issue costs) (the “Offers”). The Supplementary Prospectus is a regulatory requirement under the Prospectus Regulation Rules and Section 87G of Financial Services and Market Act 2000 following the publication of the annual report and accounts for the year ended 31 December 2020 by each of Albion Development...

            Press releaseMalmö, Sweden, April 7, 2021 Positive, long term prognostic data from the Dan-NICAD I study published in European Heart Journal- Digital Health Acarix AB (publ) today announced the publication of the Prognostic study, a study with long term follow up on patients from the Dan-NICAD 1 publication. The long term Prognostic data from the Dan-NICAD 1 trial was first presented at the ESC Congress in September 2019 by Simon Winther, MD, PhD from Aarhus University Hospital, Denmark. The Dan-NICAD 1 trial was initiated in September 2014 to assess non-invasive methods in patients referred to coronary CTA due to symptoms suggestive of obstructive CAD. Clinically relevant prognostic data were assessed with a median follow-up time of 3 years to evaluate the correlation between CAD-score and prognosis in patients treated by...

Pressmeddelande Malmö, 7 april 2021 Positiva prognostiska långtidsdata från Dan-NICAD 1-studien publiceras i European Heart Journal Digital Health Acarix AB (publ) meddelade idag publiceringen av den prognostiska studien med långsiktiga uppföljningsdata av patienter från Dan-NICAD 1-studien. De långsiktiga prognostiska data från Dan-NICAD 1-studien presenterades för första gången vid ESC-kongressen i september 2019 av Dr Simon Winther, läkare och PhD vid universitetssjukhuset i Århus, Danmark. Dan-NICAD 1-studien initierades i september 2014 för att bedöma icke-invasiva metoder hos patienter som hänvisas till CTA av kranskärlen på grund av symtom som tyder på obstruktiv kranskärlssjukdom. Kliniskt relevanta prognostiska data bedömdes med en medianuppföljningstid på tre år för att utvärdera korrelationen mellan CAD-scoretestresultat och...

Det skal hermed meddeles, at Investeringsforeningen Danske Invest afholder fælles ordinær generalforsamling med Investeringsforeningen Danske Invest Select og Investeringsforeningen Danske Invest Index mandag d. 26. april 2021, kl. 16.00 på foreningernes kontor, Parallelvej 17, 2800 Kgs. Lyngby. Grundet den særlige situation omkring COVID-19 henstiller vi til, at ingen investorer møder fysisk op til generalforsamlingen og gør opmærksom på, at der ikke vil være drikkevarer eller andet traktement i forbindelse med generalforsamlingen. Dagsordenen er vedhæftet. Med venlig hilsen DANSKE INVESTMANAGEMENT A/S Robert Mikkelstrupadm. direktør Vedhæftet filDI – DIS – DIX GF dagsorden + Bilag – 26.04.2021

Press Release Nokia and Lenovo conclude patent cross-licensing agreement 7 April 2021 Espoo, Finland – Nokia and Lenovo conclude patent cross-licensing agreement. Nokia announced today that it has concluded a multi-year, multi-technology patent cross-license agreement with Lenovo. Under the agreement, Lenovo will make a net balancing payment to Nokia. The terms of the agreement remain confidential. The agreement resolves all pending patent litigation and other proceedings between the two parties, in all jurisdictions. Jenni Lukander, President of Nokia Technologies, said: “We are delighted to have reached an agreement with Lenovo. The agreement reflects Nokia’s decades-long investments in R&D and contributions to cellular and multimedia standards. We appreciate, and very much respect, the constructive spirit Lenovo brought to our...

Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines  Launch of a new and more impactful global corporate social responsibility strategy Accelerating projects on access to medicines, support for vulnerable communities, environmental conservation, and diversity and inclusion Creation of Sanofi Global Health, global nonprofit unit to provide 40 of the world’s poorest countries access to 30 essential medicinesPARIS – April 7, 2021 – In an open letter, Sanofi Chief Executive Officer Paul Hudson today outlined several key projects that the company will implement to increase the impact of its Corporate Social Responsibility (CSR) strategy. Embedded in Sanofi’s long-term strategy, the company’s commitment is based on four essential pillars in which Sanofi is uniquely...